Premium
Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis ( ADDRESS ‐J): Baseline characteristics, treatment history and disease burden
Author(s) -
Katoh Norito,
Saeki Hidehisa,
Kataoka Yoko,
Etoh Takafumi,
Teramukai Satoshi,
Takagi Hiroki,
Tajima Yuki,
Ardeleanu Marius,
Rizova Elena,
Arima Kazuhiko
Publication year - 2019
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.14787
Subject(s) - medicine , atopic dermatitis , observational study , eczema area and severity index , disease , disease registry , population , cohort , quality of life (healthcare) , disease burden , cohort study , dermatology , environmental health , nursing
Moderate to severe atopic dermatitis ( AD ) has a high disease burden and a significant effect on quality of life. Observational studies are necessary to determine the patient disease burden and long‐term disease control in the Japanese population. ADDRESS ‐J is a non‐interventional, observational registry of adult Japanese patients with moderate to severe AD . Herein, we report baseline data from the ADDRESS ‐J study describing disease characteristics and current treatment practices. At baseline, 300 adult AD patients with Investigator's Global Assessment ( IGA ) scores (range, 0–4) of 3 (moderate) or 4 (severe) whose treatments for AD were intensified, were assessed for clinical and patient‐reported outcomes and current AD treatments. The registry patients’ median age was 34.0 years; 60.7% were male and 71.7% had had AD for more than 20 years. At baseline, 220 study patients had an IGA score of 3 and 80 had an IGA score of 4. The median Eczema Area and Severity Index score was 21.7 (range, 0–72), the median body surface area involvement was 46.25%, and the median pruritus numerical rating scale score was 7.0 (range, 0–10); for each of these measures, higher scores represent greater severity. Most registry patients (86.7%) had recently used topical corticosteroids or topical calcineurin inhibitors as treatment for AD . This registry cohort represents a population of Japanese patients with moderate to severe AD and provides an important resource for characterizing the disease burden and evaluating the safety and effectiveness of various AD treatments.